Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
EP Vantage FDA Approval Rates: Niche Products Driving Record Success
Our latest report EP Vantage FDA Approval Rates: Niche Products Driving Record Success, shows that a focus on hard to treat or specialist diseases is set to result in record post-launch sales for new drugs in 2013.
While the total tally of approved drugs and biologics for 2013 is not forecast to match last year’s record of 43, the combined US sales for this year’s approved products could surpass $18bn five years after launch. The report is based on market intelligence and analysis from EvaluatePharma and is the first in a new series of shorter reports from EP Vantage.
Key findings include:
- Since January 1, to November 11, 2013, the FDA has approved 27 new compounds with another seven hopefuls awaiting approval.
- Of the 27 drugs approved so far, combined fifth-year U.S. sales are forecast to reach $13.9bn.
- Tecfidera ranks No. 1 among top five approvals of 2013 (January to November, 11) with sales estimated at $2.9bn by 2018.
- If approved in 2013, Gilead Sciences’ sofosbuvir stands to become this year’s most valuable new molecule, with fifth-year US sales estimated at almost $3bn.
EP Vantage Medtech Half-Year Review 2013
EP Vantage Pharma Half-Year Review 2013
EP Vantage 2012 Year in Review